LLY

934

+3.03%↑

JNJ

186.56

-0.2%↓

UNH

327.16

-0.95%↓

NVS

125.6

+0.39%↑

ABT

124.77

-0.56%↓

LLY

934

+3.03%↑

JNJ

186.56

-0.2%↓

UNH

327.16

-0.95%↓

NVS

125.6

+0.39%↑

ABT

124.77

-0.56%↓

LLY

934

+3.03%↑

JNJ

186.56

-0.2%↓

UNH

327.16

-0.95%↓

NVS

125.6

+0.39%↑

ABT

124.77

-0.56%↓

LLY

934

+3.03%↑

JNJ

186.56

-0.2%↓

UNH

327.16

-0.95%↓

NVS

125.6

+0.39%↑

ABT

124.77

-0.56%↓

LLY

934

+3.03%↑

JNJ

186.56

-0.2%↓

UNH

327.16

-0.95%↓

NVS

125.6

+0.39%↑

ABT

124.77

-0.56%↓

Search

WaVe Life Sciences Ltd

Avatud

7.94 -1

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.71

Max

8.05

Põhinäitajad

By Trading Economics

Sissetulek

-3.6M

-50M

Müük

-476K

8.7M

Kasumimarginaal

-580.17

Töötajad

287

EBITDA

-2.9M

-51M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+156.55% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

10. nov 2025

Turustatistika

By TradingEconomics

Turukapital

51M

1.3B

Eelmine avamishind

8.94

Eelmine sulgemishind

7.94

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

WaVe Life Sciences Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. nov 2025, 23:57 UTC

Tulu

Naver's Third-Quarter Earnings Rose on AI Push

4. nov 2025, 23:10 UTC

Omandamised, ülevõtmised, äriostud

Kennedy-Wilson Gets Acquisition Proposal From CEO, Fairfax Financial

4. nov 2025, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. nov 2025, 23:48 UTC

Market Talk

Nikkei May Fall After U.S. Tech Stock Weakness -- Market Talk

4. nov 2025, 23:37 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

4. nov 2025, 23:30 UTC

Tulu

Itau Unibanco 3Q Net BRL33.7B >ITUB

4. nov 2025, 23:25 UTC

Tulu

Naver 3Q Net Profit Beat FactSet-Compiled Consensus

4. nov 2025, 23:25 UTC

Tulu

Naver 3Q Net KRW734.70B Vs. Net KRW530.10B >035420.SE

4. nov 2025, 23:24 UTC

Tulu

Naver 3Q Oper Pft KRW570.60B Vs. Pft KRW525.30B >035420.SE

4. nov 2025, 23:23 UTC

Tulu

Naver 3Q Rev KRW3.138T Vs. KRW2.716T >035420.SE

4. nov 2025, 23:06 UTC

Tulu

Review & Preview: Tech Check -- Barrons.com

4. nov 2025, 22:52 UTC

Tulu

AMD Reports Sharply Higher Profits, Sales -- 3rd Update

4. nov 2025, 22:33 UTC

Tulu

AMD Beats Earnings. The Stock Still Slides. -- Barrons.com

4. nov 2025, 22:29 UTC

Tulu

Ashland 4Q Adj EPS $1.08 >ASH

4. nov 2025, 22:29 UTC

Tulu

Ashland Sees FY26 Adjusted EPS Up More Than Double Digits >ASH

4. nov 2025, 22:28 UTC

Tulu

Ashland Sees FY26 Sales $1.84B-$1.91B >ASH

4. nov 2025, 22:27 UTC

Tulu

Ashland 4Q Cont Ops EPS 73c >ASH

4. nov 2025, 22:27 UTC

Tulu

Ashland 4Q EPS 71c >ASH

4. nov 2025, 22:27 UTC

Tulu

Ashland 4Q Sales $478M >ASH

4. nov 2025, 22:23 UTC

Tulu

Ovintiv 3Q EPS 57c >OVV

4. nov 2025, 22:19 UTC

Market Talk

Canada Budget: Snap Election Talk Might Cool -- Market Talk

4. nov 2025, 22:16 UTC

Tulu

AMD Reports Sharply Higher Profits, Sales -- 2nd Update

4. nov 2025, 22:14 UTC

Omandamised, ülevõtmised, äriostud

Kennedy-Wilson Board Forms Special Committee to Evaluate Proposal

4. nov 2025, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Consortium: Not Interested in Selling Kennedy-Wilson Shares to Another Party

4. nov 2025, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Consortium: Able to Finance a Deal With Available Liquidity

4. nov 2025, 22:12 UTC

Omandamised, ülevõtmised, äriostud

Consortium Owns About 31% of Kennedy-Wilson Stock on As-Converted Basis

4. nov 2025, 22:11 UTC

Tulu

Private-Credit Earnings Ease Investor Concern Over Market's Health -- Update

4. nov 2025, 22:11 UTC

Omandamised, ülevõtmised, äriostud

Kennedy-Wilson Gets Proposal From CEO William McMorrow and Fairfax Financial Holdings

4. nov 2025, 22:10 UTC

Omandamised, ülevõtmised, äriostud

Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup -- 2nd Update

4. nov 2025, 22:07 UTC

Tulu

Kinross Gold Raises Dividend to $0.035 >K.T

Võrdlus sarnastega

Hinnamuutus

WaVe Life Sciences Ltd Prognoos

Hinnasiht

By TipRanks

156.55% tõus

12 kuu keskmine prognoos

Keskmine 20.55 USD  156.55%

Kõrge 36 USD

Madal 12 USD

Põhineb 11 Wall Streeti analüütiku instrumendi WaVe Life Sciences Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

11

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

6.35 / 6.555Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

help-icon Live chat